Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Puma Biotech secures $100 million loan to market its breast cancer drug - L.A. Business First
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Fillable Online Puma biotechnology, inc. form s-1/a - Biotech Due Diligence Fax Email Print - pdfFiller
Puma Biotechnology
Puma Biotechnology, Inc.
SEC charges former Puma biotech exec with $1.1 million in insider trading
Selloff of Puma is an overaction: Analyst
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotech's Breast Cancer Drug Results Mint New Billionaire Overnight
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech plunges on drug side effects
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology Surging
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology, Inc. | LinkedIn
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Articles with Puma Biotechnology
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
